Future Science Group
FutureOncology_Supplement_v2.0_Resubmission(1).docx (471.16 kB)
Download file

Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs - supplementary material

Download (471.16 kB)
posted on 2023-06-07, 08:51 authored by Mufiza Farid-Kapadia, Madelyn Barton, Zoe Bider-Canfield, Parneet K Cheema, Bishal Gyawali, Natalie M Nightingale, Lidija Latifovic, Henry J Conter


Supplementary Table 1: Tumor-Specific Trial Search Strategy


Supplementary Table 2: Tumor-Agnostic Trial Search Strategy


Exhibit 3: Tumor-agnostic trial characteristics


Supplementary Table 4: Tumor-agnostic cohort characteristics


Supplementary Table 5: Progression-free survival (PFS) and overall survival (OS) estimates from tumor-agnostic trials.


Supplementary Table 6: Tumor-specific trial characteristics


Supplementary Table 7: Tumor-specific cohort characteristics


Supplementary Table 8. Progression-free survival (PFS) and overall survival (OS) estimates from tumor-specific trials. 


Supplementary Figure 1: Meta-analysis of BRAF inhibitors by trial type.


Supplementary Figure 2: Meta-analysis of BRAF/MEK inhibitors by trial type.


Hoffman La Roche, (Grant / Award Number)


Usage metrics

    Future Oncology